Scientists found the hidden switch fueling alzheimer’s brain inflammation - ScienceDaily

USC scientists have reportedly discovered the "hidden switch" fueling destructive brain inflammation in Alzheimer's disease, unveiling a novel compound, NeuroGen-17, that can selectively disarm it. Published in Nature Neuroscience, this breakthrough identifies an overactive microglial receptor, modulated by the TREM2 pathway, as a critical driver of neurodegeneration, shifting the paradigm beyond decades of focus purely on amyloid-beta and tau pathologies. This targeted approach offers a potent new therapeutic avenue for a disease that currently has no cure. For years, the field has grappled with the dual nature of neuroinflammation: essential for brain health yet devastating when dysregulated. Earlier attempts to quell inflammation broadly often failed in clinical trials, suggesting a lack of specificity. The USC team's work addresses this directly by isolating the maladaptive inflammatory response, providing a crucial distinction from beneficial immune functions. This comes at a time when other major drug candidates, like Eisai's Leqembi, have shown modest efficacy in slowing early-stage Alzheimer's, underscoring the urgent need for diverse therapeutic strategies. While still in preclinical trials, NeuroGen-17 highly selective mechanism has generated significant excitement within the neuroscientific community. Researchers at USC Zilkha Neurogenetic Institute are now fast-tracking advanced toxicology and efficacy studies, with an eye towards securing FDA fast-track designation and initiating human trials potentially by late 2027. Success could redefine Alzheimer's treatment, moving towards earlier, more effective intervention that directly tackles a core driver of cognitive decline, leaving investors and pharmaceutical giants closely watching the next steps.